Skip to content

Author

Xu Wang

We have 3 of 15 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Design and discovery of highly potent lysine 27 of histone H3 (H3K27) demethylase inhibitors for the treatment of inflammatory bowel disease.

Lysine specific demethylase 6A/B (KDM6A/B), histone lysine demethylases targeting H3K27me3, have emerged as key regulators of inflammatory gene expression and are increasingly implicated in the pathogenesis of inflammatory bowel disease (IBD). However, there remains a critical need for potent, selective, and cell-activ...

Yu-Qi Tang, Xin Hu, An-Cheng Shen et al. · 0 citations
Review Open access Oct 2026

Metabolic reprogramming in cancer-associated fibroblasts: orchestrating the tumor immune microenvironment and response to immune checkpoint blockade

Immune checkpoint blockade (ICB) has reshaped the therapeutic landscape of solid tumors. However, durable clinical benefit remains limited to a subset of patients because of primary or acquired resistance. Beyond tumor-intrinsic factors, the tumor microenvironment (TME) plays a critical role in shaping responsiveness t...

Luo-Man Gan, Zhong-Long Liu, Li-Ren Cao et al. · 0 citations
Open access Aug 2026

Reversing KDM6A phosphorylation-driven epigenetic suppression restores pyroptosis and synergizes with anti-PD-1 therapy in HNSCC

KDM6A phosphorylation is identified as a druggable epigenetic-immune checkpoint and mRNA-based modulation of enzyme post-translational status as a transformative paradigm to potentiate ICB in HNSCC is established.

Yi-Kang Ji, Xin-Ran Zhao, Cheng Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.